SBIO Stock Chart & Stats
C$0.12
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.12
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.52
Previous CloseN/A
Volume0.00
Average Volume (3M)21.65K
Market Cap
C$7.91M
Enterprise ValueC$20.50
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Dec 01, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding54,957,382
10 Day Avg. Volume10,981
30 Day Avg. Volume21,646
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$0.50Price Target Upside316.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)C$54.35M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceSabio reported strong Q2/25 financial results, including revenue of $11.2M (+25% YoY), compared to our estimate of $10.2M.
Future GrowthManagement remains bullish on 2026, stating that its Q1 pipeline is up 60% year-over-year.
Market PositioningSabio is set up for a catalyst-heavy year ahead, with H2/25 being seasonally stronger and 2026 featuring many political tailwinds.
Bears Say
Investment ImpactAdjusted EBITDA came in at ($1.2M), slightly lower than our projected ($0.9M) due to continued investments into growth initiatives.
Revenue DeclineSabio reported Q3 financial results that missed expectations, with revenue coming in at $8.2M, which is a 49% decline year-over-year.
Spending ShiftsManagement attributed the weak quarter to 2025 being a non-political year and clients shifting spending to prior quarters.
SBIO FAQ
What was Sabio Holdings’s price range in the past 12 months?
Sabio Holdings lowest stock price was C$0.08 and its highest was C$0.52 in the past 12 months.
What is Sabio Holdings’s market cap?
Sabio Holdings’s market cap is C$7.91M.
When is Sabio Holdings’s upcoming earnings report date?
Sabio Holdings’s upcoming earnings report date is Dec 01, 2026 which is in 67 days.
How were Sabio Holdings’s earnings last quarter?
Sabio Holdings released its earnings results on Aug 19, 2026. The company reported -C$0.099 earnings per share for the quarter, missing the consensus estimate of -C$0.028 by -C$0.071.
Is Sabio Holdings overvalued?
According to Wall Street analysts Sabio Holdings’s price is currently Undervalued.
Does Sabio Holdings pay dividends?
Sabio Holdings does not currently pay dividends.
What is Sabio Holdings’s EPS estimate?
Sabio Holdings’s EPS estimate is 0.01.
How many shares outstanding does Sabio Holdings have?
Sabio Holdings has 54,957,382 shares outstanding.
What happened to Sabio Holdings’s price movement after its last earnings report?
Sabio Holdings reported an EPS of -C$0.099 in its last earnings report, missing expectations of -C$0.028. Following the earnings report the stock price went down -10%.
Which hedge fund is a major shareholder of Sabio Holdings?
Currently, no hedge funds are holding shares in TSE:SBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sabio Holdings
Sabio Holdings, Inc. is a technology company, which engages in advertising areas of connected TV (CTV) and over-the-top (OTT) streaming activities. It engages in creating and distributing ad-supported CTV/OTT applications on platforms such as Roku, Amazon Fire, Plex, Apple TV+, Samsung TV, Vizio, and LG through its subsidiaries. The company was founded by Aziz Rahimtoola and Joe Camacho on September 27, 2017 and is headquartered in Playa Del Rey, CA.
SBIO Stock 12 Month Forecast
Average Price Target
C$0.50
▲(316.67% Upside)
Technical Analysis
Quantum Biopharma
―
Devonian Health Group
―
Optimi Health
―
Ocumetics Technology Corp
―
Thiogenesis Therapeutics Corp
―








